Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Obstructive Pulmonary Disease: full-pipeline trial registry
29 of 87 indexed Chronic Obstructive Pulmonary Disease trials are currently recruiting.
Corpus placement: #158 of 28,707 conditions by registered trial count.
87 US clinical trials · 29 currently recruiting · #158 of 28,707 conditions by registered trial count
Chronic Obstructive Pulmonary Disease: 87 US clinical trials tracked, 29 recruiting.
Chronic Obstructive Pulmonary Disease is the subject of 87 registered US clinical trials on ClinicalTrials.gov, 29 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 6 of these trials.
Enrollment posture brief
Registry condition chronic-obstructive-pulmonary-disease
OPEN 29 | RECR 33% | LATE 19 | EARLY 27 | RANK #158 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Chronic Obstructive Pulmonary Disease lists 29 open slots (33% of 87 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Obstructive Pulmonary Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Obstructive Pulmonary Disease is recruiting below its size-band peers.
29 of 87 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chronic Obstructive Pulmonary Disease trials is spread across many organizations.
Sanofi accounts for 6 of 87 trials (6.9%). 62 distinct sponsors appear on at least one study for this condition label.
-
Typical Chronic Obstructive Pulmonary Disease enrolment sits around 136 participants.
Median target enrolment is 136 among the 87 trials that report a genuine target (sentinel values excluded). 36 of those (41.4%) plan for fewer than 100 participants.
-
Chronic Obstructive Pulmonary Disease research is mostly interventional.
70 interventional and 17 observational studies make up this index (80.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
87 total, page 1 of 2
Emphysema Research Registry and Biosample Repository
University of Pittsburgh
NCT00307281
Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
Brigham and Women's Hospital
NCT01177618
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche
NCT05878769
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sanofi
NCT07190222
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi
NCT07190209
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
University of Alabama at Birmingham
NCT05119556
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Upstream Bio
NCT06981078
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Verona Pharma
NCT07016412
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT06974981
: Vascular Function in Health and Disease
Russell Richardson
NCT02966665
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
Seattle Institute for Biomedical and Clinical Research
NCT06390345
Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling
Baystate Medical Center
NCT05399056
Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management
Icahn School of Medicine at Mount Sinai
NCT06634810
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
University of California, San Diego
NCT05237505
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Sanofi
NCT07053423
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
Nuvaira
NCT07051707
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
Beth Israel Deaconess Medical Center
NCT05934565
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
Genentech
NCT06603246
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
Observational and Pragmatic Research Institute
NCT05306743
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
VA Office of Research and Development
NCT05937854
COPD Care Pathway Among Patients With Cancer
Wake Forest University Health Sciences
NCT05984680
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
Masonic Cancer Center, University of Minnesota
NCT05025774
CareCOPD - COPD Home Monitoring Study
Cognita Labs
NCT04918095
Biological Effects of Quercetin in COPD Phase II
Temple University
NCT06003270
Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy
University of Virginia
NCT03331302
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
University of Miami
NCT05607719
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
University of Nebraska
NCT06524856
Accelerated Pulmonary Rehabilitation in the Preoperative Period
University of Vermont
NCT06432972
Feasibility of Semaglutide in Advanced Lung Disease
University of Pennsylvania
NCT05746039
Study of COPD Subgroups and Biomarkers
University of North Carolina, Chapel Hill
NCT01969344
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi
NCT06208306
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Merck Sharp & Dohme
NCT05612035
Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics
University of Virginia
NCT03002389
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
Areteia Therapeutics
NCT06533553
Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects
Milton S. Hershey Medical Center
NCT05239793
Replication of the INSPIRE Trial in Healthcare Claims Data
Brigham and Women's Hospital
NCT05179512
Observational Study of Obstructive Lung Disease (NOVELTY)
AstraZeneca
NCT02760329
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
AstraZeneca
NCT01966107
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation
AstraZeneca
NCT07414134
Identifying Inflammatory Biomarkers of Chronic Obstructive Pulmonary Disease
University of Arizona
NCT00394940
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
AstraZeneca
NCT02796677
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
AstraZeneca
NCT00419744
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
AstraZeneca
NCT00076089
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Sanofi
NCT03930732
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Sanofi
NCT04456673
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Verona Pharma
NCT04535986
Veterans Integrated Service Network (VISN) 23 Lung Disease Self Management/Case Management Program
US Department of Veterans Affairs
NCT00126776
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
Sumitomo Pharma America
NCT00064402
Screening Evaluation for Studies of Chronic Obstructive Pulmonary Disease (COPD)
Johns Hopkins University
NCT00889447
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Sumitomo Pharma America
NCT00250679
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 18 |
| Phase 3 | 15 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Obstructive Pulmonary Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Obstructive Pulmonary Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Obstructive Pulmonary Disease page
87 registered trials, 29 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 29 Chronic Obstructive Pulmonary Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Chronic Obstructive Pulmonary Disease trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Obstructive Pulmonary Disease condition card totals 87 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.